The Food and Drug Administration has finalized guidance meant to help scientists work through the "unique challenges" of studying psychedelics for medical use, and has scheduled a public hearing on psychedelic therapy for September.
The document, published Monday and titled "Psychedelic Drugs: Considerations for Clinical Investigations," states that interest in psychedelics' therapeutic potential has grown in recent years. FDA notes that drug programs for substances like psilocybin, LSD and MDMA face the same regulatory standards as other drugs, but that designing trials for them poses distinct difficulties, since these substances can trigger "intense perceptual disturbances and alterations in consciousness" lasting hours or days, sometimes producing benefits after just one or a few doses.
The guidance offers recommendations on chemistry, manufacturing, abuse potential and clinical pharmacology for sponsors. It flags the risk that intense perceptual effects make it hard to keep trials properly blinded: patients, therapists or raters who notice the drug's effects may develop "expectation bias," assuming benefit will follow, while those given a placebo who feel nothing may assume there won't be improvement.
This final version builds on a 2023 draft and follows an executive order from President Donald Trump directing faster research into psychedelics' therapeutic value. FDA said it incorporated public comments on the draft and is still accepting feedback on the final guidance, per a Federal Register notice.
Separately, FDA will hold a hearing on September 14 to gather input on the possible future therapeutic use of psychedelic drug products in supervised, supportive settings. A presiding officer and FDA panelists from the Center for Drug Evaluation and Research, along with other federal representatives, will lead the session. FDA is accepting applications from parties wanting to speak on provider training and credentialing, patient safety, access considerations, and data collection standards — but says it will not entertain comment on the safety/effectiveness of specific products, Controlled Substances Act scheduling, state or local legalization efforts, religious or personal non-medical use, or individual enforcement disputes.
In April, FDA and the Department of Health and Human Services outlined steps to speed therapeutic psychedelic access for patients with serious mental health conditions. In May, 32 bipartisan members of Congress sent a letter urging FDA to accelerate its reviews of psychedelic therapies. This month, lawmakers introduced a bill requiring the Department of Defense to report on how psilocybin research could benefit military members, while a separate bipartisan bill seeks to codify Trump's psychedelics executive order into law. A pending amendment to the National Defense Authorization Act would extend DOD's psychedelics research program by six years.
